Fundamental Analysis of Tarsus Pharmaceuticals Inc - Growth / Value Index


TARS - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 2953.42 suggesting that it is very expensive
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -4886.64 -10443.50 -68777.00 %
Price to Book 2972.86 5703.98 16.87 % 4.90
Price to Sales 10351.87 78186.38 214297 %
Enterprise Value to EBITDA Multiple -8.02 -10812.74 -67245.01 %


TARS - Profitability Highlights

Profitability Analysis

   Excellent QoQ /QoQ FY EPS growth
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 2.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   EPS decline for last four quarters
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -60.84 -54.62 99.83 % -12.98
Return On Asset -47.74 -40.52 99.85 % -10.23
Net Profit Margin -211.84 -748.66 -211.28 % -129.39
Operating Profit Margin -269.53 -791.66 -221.00 % -136.47
EBITDA Margin -269.53 -722.97 -211.65 % -136.47


Highlights
Market Cap1444.77 M
Enterprise Value1250.04 M
Price/Book TTM2972.86
Outstanding Share37781.70 K
Float/ Outstanding Share63.23%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score2.00
Altman Z Score11.11
Sloan Ratio-0.070
Peter Lynch Fair Value0


TARS - Growth Highlights

Growth Analysis

   YoY Net Margin Jump by 211.28%
   Quarterly sales in last 5 years is trending up
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Very Poor Score of 18.93
   Annual sales in last 3 years is trending down
   Companies' sales dropped by 44.33 % from last year
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 57838.00 K 44.33 % 111.18 %
Gross Profit 54591.00 K 45.32 % 118.89 %
EBITDA -155890.00 K 73.49 % 15.22 %
Net Profit -122524.00 K 73.28 % 14.73 %
EPS -0.0078 99.85 % NA


TARS - Stability Highlights

Stability Analysis

   Altman Z Score of 11.02 suggests good Stability
   Cash ratio of 6.16
   Company's debt has increased with decreasing revenue.
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -34.11
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.153 -99.85 % 0.111
Cash Ratio 6.16 -56.22 %
Quick Ratio 6.85 102.33 % 7.92
Shareholders Equity 74.20 -12.35 %
Debt to EBITDA -0.291 13.58 %


Historical Valuation Ratios of Tarsus Pharmaceuticals Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Tarsus Pharmaceuticals Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Tarsus Pharmaceuticals Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Tarsus Pharmaceuticals Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)